Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH003 dose escalation in solid cancer
NCT03081819Phase 1Completed
- Sponsor
- Kyung Hee University Medical Center
- Start
- Mar 2017
- Primary completion
- Apr 2019
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of SH003 in solid tumor (3 arms), sponsored by Kyung Hee University Medical Center. Primary endpoint: Adverse events at 3 weeks. Started Mar 2017; status: completed.
02
Drugs
SH003
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03081819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081819.